Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

82.21
Delayed Data
As of Dec 02
 -1.12 / -1.34%
Today’s Change
62.12
Today|||52-Week Range
107.56
-21.53%
Year-to-Date
BioMarin Surging Beneath the Surface
Nov 29 / TheStreet.com - Paid Partner Content
5 Biotech Stocks George Soros Is Buying
Nov 22 / MotleyFool.com - Paid Partner Content
U.S. Elections: What They Might Mean for Investors - JOHCM Commentary
Nov 29 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close83.33
Today’s open83.39
Day’s range81.89 - 84.02
Volume1,142,525
Average volume (3 months)1,454,226
Market cap$14.1B
Dividend yield--
Data as of 4:00pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-16.30%
Earnings growth (this year)-248.55%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+16.29%
P/E ratioNM
Price/Sales19.22
Price/Book5.53

Competitors

 Today’s
change
Today’s
% change
PRGOPerrigo Company PLC+0.16+0.19%
VRTXVertex Pharmaceutica...-2.32-2.98%
SGENSeattle Genetics Inc-0.01-0.01%
INCYIncyte Corp+2.09+2.09%
Data as of 4:14pm ET, 12/02/2016

Financials

Next reporting dateFebruary 23, 2017
EPS forecast (this quarter)-$0.38
Annual revenue (last year)$872.2M
Annual profit (last year)-$171.8M
Net profit margin-19.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts


Search for Jobs